C3L-03462
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 61.50581793
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- TNFA_SIGNALING_VIA_NFKB+0.470
- INTERFERON_GAMMA_RESPONSE+0.450
- ANGIOGENESIS+0.430
- INFLAMMATORY_RESPONSE+0.420
- INTERFERON_ALPHA_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.350
- COMPLEMENT+0.310
- IL6_JAK_STAT3_SIGNALING+0.310
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.430
- MYC_TARGETS_V2-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- ADIPOGENESIS-0.300
- FATTY_ACID_METABOLISM-0.250
- PEROXISOME-0.240
- DNA_REPAIR-0.230
- E2F_TARGETS-0.230
- MYC_TARGETS_V1-0.230
- ESTROGEN_RESPONSE_LATE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278883 | — | — | 0.889 |
| 2 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.884 |
| 3 | ERR2208918 | — | — | 0.882 |
| 4 | TCGA-MP-A4TC-01A-11R-A24X-07 | — | cohortA1 | 0.880 |
| 5 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.880 |
| 6 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.876 |
| 7 | MDT-AP-3277 | Med | Medulloblastoma | 0.868 |
| 8 | c6396737-3587-46a7-808d-963eebe41224 | — | — | 0.866 |
| 9 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.863 |
| 10 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |